Table 1.
Baseline characteristics stratified by tertile according to T50
| Overall (N=932) |
Tertile 1 (<235 min) (N=311) |
Tertile 2 (235–293 min) (N=310) |
Tertile 3 (>293 min) (N=311) |
|
| Age (years) | 65.8 (58.5–72.0) | 65.7 (57.9–71.7) | 65.7 (59.7–72.3) | 65.9 (58.7–71.7) |
| Sex, % male (n) | 54.7 (510) | 44.7 (139) | 53.9 (167) | 65.6 (204) |
| Smoking, % current (n) | 17.0 (157) | 23.7 (73) | 15.2 (47) | 12.0 (37) |
| Alcohol use, % (n) | 36.1 (273) | 30.1 (78) | 38.2 (91) | 40.2 (104) |
| BMI (kg/m²) | 29.3 (26.7–33.0) | 29.7 (27.1–33.4) | 29.1 (26.4–32.8) | 29.1 (26.7–32.7) |
| SBP (mm Hg) | 135 (125-144) | 136 (124-145) | 135 (125-144) | 134 (125-141) |
| DBP (mm Hg) | 80 (70-83) | 80 (72-84) | 76 (70-82) | 80 (72-82) |
| Duration of diabetes (years) | 6.5 (3.0–10.2) | 6.7 (3.2–10.5) | 7.2 (2.9–10.5) | 5.9 (2.79.7) |
| HbA1c (mmol/mol) | 49 (44-54) | 50 (45-55) | 49 (43-54) | 48 (44-53) |
| Total cholesterol (mmol/L) | 4.3 (3.7–4.9) | 4.2 (3.7–4.9) | 4.3 (3.7–4.9) | 4.3 (3.7–4.8) |
| HDL cholesterol (mmol/L) | 1.2 (1.0–1.5) | 1.3 (1.0–1.5) | 1.2 (1.1–1.5) | 1.2 (1.0–1.4) |
| Total cholesterol/HDL ratio | 3.4 (2.8–4.2) | 3.3 (2.7–4.3) | 3.4 (2.8–4.1) | 3.5 (2.9–4.3) |
| LDL cholesterol (mmol/L) | 2.3 (1.8–2.8) | 2.2 (1.7–2.8) | 2.4 (1.8–2.8) | 2.3 (1.9–2.9) |
| Triglycerides (mmol/L) | 1.5 (1.1–2.0) | 1.5 (1.1–2.1) | 1.4 (1.0–2.0) | 1.5 (1.0–2.1) |
| History of macrovascular event, % (n) | 25.1 (234) | 25.4 (79) | 23.5 (73) | 26.4 (82) |
| History of AP, % (n) | 7.4 (59) | 5.8 (18) | 7.1 (22) | 9.3 (29) |
| History of MI, % (n) | 8.6 (80) | 9.6 (30) | 5.8 (18) | 10.3 (32) |
| History of PCI, % (n) | 2.6 (24) | 3.5 (11) | 2.3 (7) | 1.9 (6) |
| History of CABG, % (n) | 4.9 (46) | 5.5 (17) | 4.8 (15) | 4.5 (14) |
| History of TIA, % (n) | 3.3 (31) | 1.6 (5) | 4.5 (14) | 3.9 (12) |
| History of stroke, % (n) | 6.1 (57) | 5.5 (17) | 7.4 (23) | 5.5 (17) |
| History of microvascular event, % (n) | 35.2 (293) | 35.4 (97) | 35.3 (97) | 34.9 (99) |
| History of retinopathy, % (n) | 4.6 (38) | 7.3 (20) | 2.2 (6) | 4.3 (12) |
| History of peripheral neuropathy, % (n) | 19.7 (171) | 18.5 (53) | 20.7 (60) | 19.7 (58) |
| History of albuminuria, % (n) | 13.7 (128) | 13.8 (43) | 13.5 (42) | 13.8 (43) |
| eGFR, mL/min/1.73 m² | 74 (61-86) | 73 (60-89) | 73 (61-85) | 75 (63-87) |
| Albumin/creatinin ratio | 0.8 (0.4–1.5) | 0.7 (0.4–1.5) | 0.8 (0.4–1.5) | 1.0 (0.4–1.5) |
| Diet, % (n) | 19.4 (181) | 17.2 (53) | 19.0 (59) | 22.2 (69) |
| Oral glucose lowering drugs, % (n) | 78.1 (728) | 79.4 (247) | 79.0 (245) | 75.9 (236) |
| Insulin therapy, % (n) | 13.0 (121) | 16.4 (51) | 12.3 (38) | 10.3 (32) |
| Cholesterol-lowering drugs, % (n) | 79.6 (741) | 77.2 (240) | 82.3 (255) | 79.4 (246) |
| Antihypertensive therapy, % (n) | 84.7 (788) | 84.8 (263) | 85.2 (264) | 84.2 (261) |
Data are presented as percentage (number), mean (SD) or median (IQR).
AP, angina pectoris; BMI, body mass index; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; TIA, transient ischemic attack.